GSK1120212 Rollover Study
This was an open-label study to permit subjects with solid tumors or leukemia, who were clinically benefitting on another GSK sponsored trial with GSK1120212 either monotherapy or in combination continued access to GSK1120212.
Cancer
DRUG: GSK1120212|DRUG: Docetaxel + GSK1120212|DRUG: Erlotinib + GSK1120212|DRUG: Pemetrexed + GSK1120212|DRUG: Carboplatin + GSK1120212|DRUG: Nab-paclitaxel + GSK1120212|DRUG: Gemcitabine + GSK1120212|DRUG: Everolimus + GSK1120212
Number of Participants With Adverse Events, Number of participants with adverse events as a measure of safety and tolerability, Until 30 days after the last dose of study treatment. Subjects may have continued to receive study treatment until disease progression, death, unacceptable toxicity or until locally commercially available. The maximum duration of exposure was 76 months.
This was an open-label study to permit subjects with solid tumors or leukemia, who were clinically benefitting on another GSK sponsored trial with GSK1120212 either monotherapy or in combination continued access to GSK1120212.